GPCR & Muscarinic Electrophysiology

Unlocking GPCR Drug Discovery Through Native Circuit Electrophysiology

Bridging the translational gap between recombinant receptor binding and functional central nervous system therapeutic efficacy.

Consult with an Expert

Spotlight on Psychiatry

Muscarinic GPCRs & Circuit Restoration

The clinical approval of KarXT (xanomeline-trospium; branded as Cobenfy)—the first muscarinic-targeting antipsychotic—represents a major paradigm shift in treating schizophrenia, moving beyond traditional dopamine D₂ receptor blockade. Xanomeline (the centrally-active component) is combined with trospium chloride, a peripherally-acting muscarinic antagonist that limits cholinergic side effects, allowing central therapeutic activity to predominate. Developing the next generation of muscarinic agents requires electrophysiological validation across complex neural loops.

Thalamic Reticular Nucleus (TRN) & Oscillatory Gating

The TRN acts as a central regulator of thalamocortical transmission. Slice electrophysiology in intact thalamic tissue demonstrates that M₂ and M₄ muscarinic receptors modulate burst versus tonic firing modes in TRN GABAergic neurons. These cellular responses directly dictate delta, gamma, and sleep spindle oscillations—rhythms critical for sensory filtering and cognitive function that are severely disrupted in psychiatric conditions.

Corticostriato-Thalamo-Cortical (CSTC) Loop Modulation

Electrophysiology in intact tissue reveals how muscarinic agents (M₁, M₂, M₄, M₅) tune neurotransmission across CSTC loops, prefrontal cortex, striatum, and hippocampus. This targeted modulation enhances cortical glutamate and acetylcholine release while restraining striatal hyper-dopaminergic tone.

Addressing Full Symptom Domains (RDoC Alignment)

Evaluating GPCR activity in intact neuronal circuits maps drug effects directly to Research Domain Criteria (RDoC) constructs. This approach confirms efficacy across positive, negative, and cognitive symptom domains while verifying the absence of traditional D₂-mediated extrapyramidal and metabolic side effects.

Disease-Relevant Receptor Changes

Post-mortem studies consistently report reduced M₁ and M₄ muscarinic receptor expression in the hippocampus and prefrontal cortex of people with schizophrenia—the same regions central to cognitive and negative symptom domains. This disease-associated receptor loss cannot be recapitulated in recombinant cell systems, making native tissue electrophysiology essential for biologically valid pharmacological assessment of new muscarinic drugs. (Morris & Pratt, 2026)

The GPCR Translation Gap

Why Non-Neuronal Cell Lines Fall Short

G-protein coupled receptor (GPCR) drug discovery programmes frequently rely on high-throughput functional assays conducted in transfected, recombinant cell lines. However, non-neuronal, proliferating, or tumour-derived peripheral host cells fail to capture the physiological complexity of the central nervous system (CNS).

Receptor Reserve & Functional Efficacy

Recombinant in vitro systems often express artificially high receptor densities, creating a “receptor reserve” that artificially inflates a compound’s apparent functional efficacy. In contrast, native neuronal receptor expression varies widely across specific cell types and brain regions. For example, lower M₁ receptor reserve in the prefrontal cortex compared to other brain regions significantly alters the functional efficacy and partial agonism of M₁ ligands in vivo.

Native Signalling & Biased Agonism

Recombinant screens fail to replicate complex signalling environments present in native neurons, including non-canonical pathways, biased intracellular signalling, persistent ligand-induced desensitisation via JNK signalling, and endogenous receptor dimerisation.

Neurexpert Data

M₄ Allosteric Modulation in Native Hippocampal Tissue

Concentration-dependent potentiation of carbachol by a muscarinic M₄ positive allosteric modulator (PAM), and inhibition by a negative allosteric modulator (NAM), recorded as field excitatory postsynaptic potentials (fEPSPs) in the CA1 region of the hippocampus, evoked by stimulation of the Schaffer collaterals.

fEPSP waveforms

Responses in vehicle and with increasing concentrations of the M₄ PAM.

Traces are shown side by side, starting with vehicle, on a common scale (scale bars: 1 mV, 10 ms). Arrows (Stim.) mark the time at which the stimulus is applied to evoke the fEPSP. The stimulus artefact has been blanked for clarity. Light 3-point smoothing applied for display.

Time course of carbachol application

Carbachol applied at increasing concentrations in the presence of the M₄ PAM.

fEPSP slope normalised to baseline; each point is the mean ± SEM of 1-min bins. Shaded bands mark the 7-minute period each carbachol concentration (1, 3, 10 and 30 µM) was applied, starting 10 minutes into the recording. Vehicle n = 6; PAM 3 nM n = 6, 30 nM n = 8, 300 nM n = 6, 3000 nM n = 6.

Carbachol concentration–response

The PAM shifts carbachol potency to the left in a concentration-dependent manner.

Condition	n	EC₅₀ (µM)	Bottom (%)	Hill slope	Shift vs vehicle
Vehicle	6	7.36	25	0.85	1.0×
PAM 3 nM	6	5.82	35	1.07	1.3×
PAM 30 nM	8	4.49	27	1.04	1.6×
PAM 300 nM	6	1.83	28	0.99	4.0×
PAM 3000 nM	6	0.30	29	0.99	24.1×

Mean ± SEM, with a standard four-parameter logistic concentration–response equation fitted on a logarithmic concentration axis (top fixed at 100% baseline; bottom, EC₅₀ and Hill slope fitted).

Bidirectional allosteric modulation of carbachol

An M₄ PAM shifts the carbachol concentration–response curve to the left; an M₄ NAM reduces the carbachol response, limiting the maximal effect.

Carbachol alone (vehicle) and in the presence of 10 µM PAM or 10 µM NAM; mean ± SEM, n = 6 per group, with fitted concentration–response curves. Significance versus vehicle: * and + P < 0.05; ** and ++ P < 0.01; +++ P < 0.001 (* PAM, + NAM). The NAM reduced the response at every carbachol concentration tested, and the difference from vehicle increased with carbachol concentration, consistent with a reduction in maximal effect (efficacy) rather than a shift in potency. Curves are four-parameter logistic fits to the group means (top fixed at 100%; bottom, EC₅₀ and Hill slope fitted).

All data are unpublished.

Regional Coverage

Beyond the Hippocampus

Receptor reserve and subtype expression may vary between brain regions, so we apply the same native-tissue electrophysiology approach across the areas most relevant to your target, including prefrontal cortex, striatum and thalamus. This shows where, and how strongly, a compound acts, not just whether it acts, and for muscarinic programmes that regional profile is often where the translational story is won or lost.

Key Reference

Ready to test your GPCR programme in native tissue?

We believe that better functional data leads to better CNS medicines. Every experiment we run is designed to give your programme the clarity it needs to move forward with confidence.